Drug Type Trispecific T-cell engager (TriTE) |
Synonyms ZG 006, ZG-006, ZG006 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Breakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Lung Small Cell Carcinoma | Phase 3 | China | 23 Sep 2025 | |
Neuroendocrine Carcinoma | Phase 2 | - | 01 Aug 2025 | |
Prostate Neuroendocrine Carcinoma | Phase 2 | China | 10 Jun 2025 | |
Large cell neuroendocrine carcinoma of lung | Phase 2 | China | 13 Aug 2024 | |
Advanced Neuroendocrine Carcinoma | Phase 2 | China | 12 Aug 2024 | |
Advanced Lung Small Cell Carcinoma | Phase 2 | China | 19 Oct 2023 | |
Small Cell Lung Cancer | Phase 1 | United States | 31 Mar 2025 |
Phase 2 | 17 | qobnlxbagu(oddhfktwqh) = xepdpifpes lekuidyzkq (quurzhieqh ) View more | Positive | 30 May 2025 | |||
Phase 1 | 45 | fjttavwnvz(gttrjusykt) = sfeqzwpazz bhixzyffyq (eobonccxau ) View more | Positive | 30 May 2025 | |||
Phase 2 | 40 | fduwodnecf(ywfsnatqud) = jofhkbaush wmzzmkhayn (ebyfpijlem ) View more | Positive | 30 May 2025 | |||
fduwodnecf(ywfsnatqud) = gucvavoxpo wmzzmkhayn (ebyfpijlem ) View more | |||||||
Phase 1/2 | 24 | hupzbjjnwk(qvfaawoylr) = 绝大多数治疗相关不良事件(TRAEs)的严重程度为1级或2级。最常见的TRAEs为发热、贫血和细胞因子释放综合征(CRS,3级CRS 1例)。 dmjcpamdhs (snpogxfcxt ) View more | Positive | 25 Sep 2024 |